TX-MAVENIR
24.3.2021 14:02:05 CET | Business Wire | Press release
Mavenir, the industry’s only end-to-end cloud-native Network Software Provider and a leader in accelerating software network transformation for communications service providers (CSPs), was recognized for “Best Telecom Service Innovation” for its innovation in the delivery of fully containerized, cloud-native IMS as well as “Best Open RAN Technology” for its Virtualized Open RAN at the 5G Middle East and North Africa (MENA) Digital Symposium virtual awards.
Both awards are a demonstration of Mavenir’s dedication to developing innovative solutions for CSPs as they roll out 5G networks, achieve web-scale economics, increase productivity, and leverage current network investments.
“In order to rise to the challenges and demands operators face, Mavenir recognizes that cloud-native architecture and open interfaces are the only way forward, minimizing human intervention and driving efficient resource utilization,” said Mark Charman, Mavenir’s VP Middle East and Africa, who accepted the award. “Mavenir is honored to be recognized for our technology and innovation and our commitment for the advancement of software driven, cloud native telecoms solutions in the MENA region.”
Presenting the awards, Srushti Ghisad, Research Manager from Omdia said: “Mavenir's world’s first fully containerized, virtualized Open RAN has the flexibility to support various deployment scenarios - the main objective behind Open RAN - with clear commercial benefits. Mavenir's fully containerized cloud-native IMS demonstrates scalability, flexibility, and most importantly automation.”
Mavenir’s fully containerized, OpenRAN vRAN solution enables operators to rapidly deploy new features into the network, without waiting for new hardware revisions, or even having to forklift the hardware. It is easy to migrate from 4G to 5G with just a software update, and operators can customize their own software and put features of their choice in their network.
As the #1 IMS provider of NFV IMS, voice, video, and messaging, Mavenir transforms mobile networks with a fully virtualized and containerized cloud-native IMS platform where devices, applications, and services can run on an automated network using open architecture, containers, and artificial intelligence.
The 5G MENA awards , organized by Informa Tech, is an annual celebration of excellence and innovation in the MENA Region, held virtually on 22 March 2021 to award the most innovative and cutting-edge solutions for 5G core technology, RAN, and service innovation.
About Mavenir:
Mavenir is the industry's only end-to-end, cloud-native Network Software and Solutions/Systems Integration Provider, focused on accelerating software network transformation. Mavenir offers a comprehensive end-to-end product portfolio across every layer of the network infrastructure stack for communications service providers and enterprises. From 5G application layers (VoLTE, Messaging) to Packet Core and RAN, Security, Edge Analytics and AI, Mavenir leads the way in evolved, cloud-native networking solutions enabling innovative and secure experiences for end users.
Leveraging innovations in Mobile Core with IMS (VoLTE, VoWiFi, Advanced Messaging/RCS), and Packet Core (vEPC, 5G Core) as well as Radio Access/Edge (OpenRAN), Private Networks, as well as Mobile Services and Applications such as Digital Enablement. Mavenir accelerates digital network transformation for more than 250+ CSP customers in over 120 countries, which serve over 50% of the world’s subscribers. www.mavenir.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210324005093/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom